We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth Group (UNH) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
UnitedHealth Group (UNH - Free Report) closed at $417.99 in the latest trading session, marking a -1.73% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.72% for the day. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.12%.
The largest U.S. health insurer's shares have seen an increase of 6.48% over the last month, not keeping up with the Medical sector's gain of 12.48% and outstripping the S&P 500's loss of 0.9%.
Investors will be eagerly watching for the performance of UnitedHealth Group in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 16, 2026. The company's upcoming EPS is projected at $4.84, signifying a 18.63% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $110.05 billion, indicating a 1.4% decline compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $18.32 per share and revenue of $443.74 billion, indicating changes of +12.05% and -0.85%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for UnitedHealth Group. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% higher. Currently, UnitedHealth Group is carrying a Zacks Rank of #2 (Buy).
Investors should also note UnitedHealth Group's current valuation metrics, including its Forward P/E ratio of 23.22. This expresses a premium compared to the average Forward P/E of 21.42 of its industry.
It's also important to note that UNH currently trades at a PEG ratio of 1.71. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - HMOs industry had an average PEG ratio of 1.41.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 20, which puts it in the top 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
UnitedHealth Group (UNH) Stock Declines While Market Improves: Some Information for Investors
UnitedHealth Group (UNH - Free Report) closed at $417.99 in the latest trading session, marking a -1.73% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.72% for the day. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.12%.
The largest U.S. health insurer's shares have seen an increase of 6.48% over the last month, not keeping up with the Medical sector's gain of 12.48% and outstripping the S&P 500's loss of 0.9%.
Investors will be eagerly watching for the performance of UnitedHealth Group in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 16, 2026. The company's upcoming EPS is projected at $4.84, signifying a 18.63% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $110.05 billion, indicating a 1.4% decline compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $18.32 per share and revenue of $443.74 billion, indicating changes of +12.05% and -0.85%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for UnitedHealth Group. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% higher. Currently, UnitedHealth Group is carrying a Zacks Rank of #2 (Buy).
Investors should also note UnitedHealth Group's current valuation metrics, including its Forward P/E ratio of 23.22. This expresses a premium compared to the average Forward P/E of 21.42 of its industry.
It's also important to note that UNH currently trades at a PEG ratio of 1.71. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - HMOs industry had an average PEG ratio of 1.41.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 20, which puts it in the top 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.